University of Michigan Medical School 
Department of Internal Medicine 
and the Clinical Research Center 
CONSENT FORM , , ^ 
Informed Consent 
(To be read by the Patient and explained 
to the Patient by his or her Physician) . 
PROTOCOL : A Molecular Genetic Intervention for AIDS — 
Effects of a Transdominant Negative Form of Rev 
PRINCIPAL INVESTIGATOR: Gary J. Nabel, M.D., Ph.D. 
ASSOCIATE INVESTIGATORS: Dennis Schaberg, M.D. 
PROTOCOL NUMBER: DATE: 
PATIENT NAME: HOSPITAL NO.: 
INTRODUCTION 
We invite you to participate in a research study at the University of 
Michigan Medical Center. Several general principles apply to all who take 
part in any experimental studies: 
(1) Your participation in this study is voluntary 
(2) You may not personally benefit from this study, 
but knowledge may be gained from it that will benefit others 
(3) You may withdraw from the study at any time for any reason 
without jeopardizing your further care. 
i 
The nature of the study, the risks, inconveniences, discomforts, and 
other information are discussed in the following sections. Please do not 
hesitate to discuss any questions you have about this study with the 
physicians who explain it to you. 
DESCRIPTION OF TREATMENT OR PROCEDURE TO BE UNDERTAKEN 
As you are aware, you have an infection caused by the human 
deficiency virus (HIV) . Infection by this virus leads to an acquired 
immunodeficiency syndrome, otherwise known as AIDS, which leads to 
weakening of your body's defense against infections, the immune system. 
At the present time, this disorder which cannot be cured by medicines. In 
this study, a treatment will be offered that may help to fight this 
disease in future patients. Because the treatment is experimental, you 
may not derive any direct benefit from it. The purpose of this study is 
to determine whether this new treatment will help to prevent the weakening 
of the immune defense system in the body. Because this is a new, 
experimental treatment, we will also be observing you to determine the 
side effects of the therapy. We will also monitor the effects of this 
treatment on cells of your immune system. 
[42] 
Recombinant DNA Research, Volume 18 
